Research Center for Emergency Medicine, Department of Clinical Medicine and Emergency Department, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark.
JAMA. 2021 Oct 26;326(16):1586-1594. doi: 10.1001/jama.2021.16628.
Previous trials have suggested that vasopressin and methylprednisolone administered during in-hospital cardiac arrest might improve outcomes.
To determine whether the combination of vasopressin and methylprednisolone administered during in-hospital cardiac arrest improves return of spontaneous circulation.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark. A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021. The last 90-day follow-up was on April 21, 2021.
Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or placebo (n = 267). The first dose of vasopressin (20 IU) and methylprednisolone (40 mg), or corresponding placebo, was administered after the first dose of epinephrine. Additional doses of vasopressin or corresponding placebo were administered after each additional dose of epinephrine for a maximum of 4 doses.
The primary outcome was return of spontaneous circulation. Secondary outcomes included survival and favorable neurologic outcome at 30 days (Cerebral Performance Category score of 1 or 2).
Among 512 patients who were randomized, 501 met all inclusion and no exclusion criteria and were included in the analysis (mean [SD] age, 71 [13] years; 322 men [64%]). One hundred of 237 patients (42%) in the vasopressin and methylprednisolone group and 86 of 264 patients (33%) in the placebo group achieved return of spontaneous circulation (risk ratio, 1.30 [95% CI, 1.03-1.63]; risk difference, 9.6% [95% CI, 1.1%-18.0%]; P = .03). At 30 days, 23 patients (9.7%) in the intervention group and 31 patients (12%) in the placebo group were alive (risk ratio, 0.83 [95% CI, 0.50-1.37]; risk difference: -2.0% [95% CI, -7.5% to 3.5%]; P = .48). A favorable neurologic outcome was observed in 18 patients (7.6%) in the intervention group and 20 patients (7.6%) in the placebo group at 30 days (risk ratio, 1.00 [95% CI, 0.55-1.83]; risk difference, 0.0% [95% CI, -4.7% to 4.9%]; P > .99). In patients with return of spontaneous circulation, hyperglycemia occurred in 77 (77%) in the intervention group and 63 (73%) in the placebo group. Hypernatremia occurred in 28 (28%) and 27 (31%), in the intervention and placebo groups, respectively.
Among patients with in-hospital cardiac arrest, administration of vasopressin and methylprednisolone, compared with placebo, significantly increased the likelihood of return of spontaneous circulation. However, there is uncertainty whether this treatment results in benefit or harm for long-term survival.
ClinicalTrials.gov Identifier: NCT03640949.
重要性:之前的试验表明,在院内心脏骤停期间给予血管加压素和甲基强的松龙可能会改善预后。
目的:确定在院内心脏骤停期间给予血管加压素和甲基强的松龙的联合治疗是否能提高自主循环恢复的可能性。
设计、地点和参与者:在丹麦的 10 家医院进行的多中心、随机、双盲、安慰剂对照试验。共有 512 名成年院内心脏骤停患者参与,研究时间为 2018 年 10 月 15 日至 2021 年 1 月 21 日。最后一次 90 天随访是在 2021 年 4 月 21 日。
干预措施:患者被随机分配接受血管加压素和甲基强的松龙(n=245)或安慰剂(n=267)联合治疗。第一次给予肾上腺素后,给予血管加压素(20IU)和甲基强的松龙(40mg)或相应的安慰剂。每给予一次肾上腺素后,给予额外剂量的血管加压素或相应的安慰剂,最多给予 4 次。
主要结果和测量:主要结局是自主循环的恢复。次要结局包括 30 天时的存活和良好的神经功能结局(Cerebral Performance Category 评分 1 或 2)。
结果:在随机分组的 512 名患者中,有 501 名符合所有纳入标准且无排除标准,纳入分析(平均[标准差]年龄,71[13]岁;男性 322 名[64%])。血管加压素和甲基强的松龙组 237 名患者中的 100 名(42%)和安慰剂组 264 名患者中的 86 名(33%)患者实现了自主循环的恢复(风险比,1.30[95%置信区间,1.03-1.63];风险差异,9.6%[95%置信区间,1.1%-18.0%];P=0.03)。在 30 天时,干预组有 23 名患者(9.7%)和安慰剂组有 31 名患者(12%)存活(风险比,0.83[95%置信区间,0.50-1.37];风险差异:-2.0%[95%置信区间,-7.5%至 3.5%];P=0.48)。在 30 天时,干预组有 18 名患者(7.6%)和安慰剂组有 20 名患者(7.6%)出现良好的神经功能结局(风险比,1.00[95%置信区间,0.55-1.83];风险差异,0.0%[95%置信区间,-4.7%至 4.9%];P>0.99)。在自主循环恢复的患者中,干预组有 77 名患者(77%)和安慰剂组有 63 名患者(73%)发生高血糖症。干预组有 28 名患者(28%)和安慰剂组有 27 名患者(31%)发生高钠血症。
结论和相关性:在院内心脏骤停患者中,与安慰剂相比,给予血管加压素和甲基强的松龙可显著提高自主循环恢复的可能性。然而,对于长期生存是否有益或有害尚不确定。
试验注册:ClinicalTrials.gov 标识符:NCT03640949。